Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether NXN-462, a selective nNOS inhibitor, is
effective in reducing pain levels in patients with post-herpetic neuralgia.